Skip to main content
Adriane Fugh-Berman on Muck Rack

Adriane Fugh-Berman

As seen in: MSN, Color Research & Application, Yahoo Canada, Yahoo News, Aol, PLOS, PLOS Medicine, The Atlantic, Chicago Tribune, Drug and Therapeutics Bulletin and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adriane

Contact Adriane, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA deleting menopause hormone drug warning risks all women's health

|
By Adriane Fugh-Berman, Judy Butler
| Kansas City Star Verified
More than 100,000 women in Kansas City and 670,000 throughout Kansas will be affected by label changes announced by FDA Commissioner Marty Makary. Getty Images On Nov. 10, the Food and Drug Administration announced that it will remove the "boxed warning" on the drug label for menopausal hormone therapy or MHT that factually links the therapy to cardiovascular disease, stroke, breast cancer and dementia.
Open in Who Shared Issue with article?

How photos shape drug stigma-and what we can do about it

|
By Jeffrey Hom, Shilpa Shah, Patricia Bencivenga, Adriane Fugh-Berman
| KevinMD.com
Well before I was a physician, I was an art history major at Bowdoin College. Beneath towering pine trees, I spent much of my time in dim lecture rooms off the quad and in the quiet galleries of Maine’s art museums, studying paintings, sculptures, and photographs to understand not just what was being portrayed, but also what they revealed about the people, places, ideas, and defining events of their time.
Open in Who Shared Issue with article?

Adriane Fugh-Berman and Judy Butler: A new Alzheimer's blood test is not good for patients

|
By Adriane Fugh-Berman, Judy Butler
| Pittsburgh Post-Gazette Verified
The Food and Drug Administration’s (FDA) approval of the first blood test to aid in the diagnosis of Alzheimer’s disease sounds like a good thing for patients, but it’s not. Here’s why. Fujirebio Diagnostics’ Lumipulse G measures the ratio of two blood proteins as a proxy for the presence of amyloid plaque in the brain. Amyloid is a sticky substance that is associated with Alzheimer’s disease; however, there is insufficient evidence to support the theory that amyloid actually causes the disease.
Open in Who Shared Issue with article?
See all 85 licensed articles (115 Total)